theophylline has been researched along with Liver Cirrhosis in 39 studies
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifteen patients with newly diagnosed cirrhotic ascites were randomized to receive either 100 mg spironolactone daily for 7 days or 250 mg theophylline on days 1, 2, 4 and 6." | 9.08 | Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study. ( Dabos, KJ; Forrest, EH; Hayes, PC; MacGilchrist, AJ; Stanley, AJ, 1998) |
| "The study group consisted of 7 patients with compensated liver cirrhosis and 10 healthy volunteers, all individuals were given a single 280 mg dose of caffeine perorally." | 7.71 | [Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ( Perlík, F; Pucelíková, T; Slanar, O, 2001) |
| "Pharmacokinetics of theophylline were determined in patients with liver cirrhosis and idiopathic portal hypertension with reference to estimated hepatic blood flow assessed by indocyanine green (ICG)." | 7.68 | [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ( Kanakubo, Y; Nomura, F; Ohnishi, K; Ohto, M; Rikihisa, T; Takeda, Y, 1991) |
| "The effect of cimetidine treatment, 1 g daily over 6 days, on the disposition of theophylline was studied in nine patients with liver cirrhosis and in nine patients without liver disease." | 7.67 | The inhibition of drug metabolism by cimetidine in patients with liver cirrhosis. ( Gugler, R; Hansen, HH; Jensen, JC; Wolf, M, 1984) |
| "Apparent pharmacokinetic parameters of caffeine elimination from the circulation were determined in 27 patients with histologically confirmed liver cirrhosis, 8 patients with miscellaneous liver disease, and 8 patients with other than liver disease." | 7.67 | Correlation of caffeine elimination and Child's classification in liver cirrhosis. ( Gerok, W; Haag, K; Holstege, A; Staiger, M, 1989) |
| "We have studied the pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis, patients with chronic renal failure, and healthy subjects, and have assessed the predictive value of routine tests of liver function and renal function (creatinine clearance) for theophylline and enprofylline total body clearances." | 7.67 | The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ( de Jong, PE; de Zeeuw, RA; Ekman, I; Gips, CH; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1988) |
| "In patients with acute hepatitis, cholestasis, and compensated or decompensated liver cirrhosis the kinetics and urinary excretion of theophylline and metabolites were investigated following intravenous administration (193 mg)." | 7.66 | Pharmacokinetics and metabolism of theophylline in patients with liver diseases. ( Lissner, R; Richter, E; Schuppan, D; Staib, AH; von Bomhard, G; Zilly, W, 1980) |
| " Therefore, the aim of this study was to evaluate the influence of chronic hepatitis (CH), liver cirrhosis (LC), and other covariates on theophylline clearance by population pharmacokinetic (PPK) analysis." | 5.56 | Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. ( Araki, H; Hirota, T; Ieiri, I; Kashihara, Y; Kurata, Y; Muraki, S, 2020) |
| " These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis." | 5.28 | A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. ( Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992) |
| " In cirrhosis the bioavailability of a flow-dependent drug increases because of both portosystemic shunting and hepatocyte dysfunction." | 5.27 | Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. ( Buccino, G; Cocciolo, M; Colli, A; Parravicini, R; Scaltrini, G, 1988) |
| " The objectives of this study were (1) to evaluate the effect of liver cirrhosis on the inhibition by fluvoxamine of the metabolic disposition of theophylline, a CYP1A2 substrate with a low-extraction ratio, to assess whether decreased sensitivity to CYP1A2 inhibition in liver disease is a general characteristic of CYP1A2 substrates, regardless of their pharmacokinetic properties, and (2) to investigate the mechanism(s) underlying the effect of liver dysfunction on CYP1A2 inhibition." | 5.12 | Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. ( De Martin, S; Orlando, R; Padrini, R; Palatini, P; Perazzi, M; Piccoli, P, 2006) |
| "Fifteen patients with newly diagnosed cirrhotic ascites were randomized to receive either 100 mg spironolactone daily for 7 days or 250 mg theophylline on days 1, 2, 4 and 6." | 5.08 | Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study. ( Dabos, KJ; Forrest, EH; Hayes, PC; MacGilchrist, AJ; Stanley, AJ, 1998) |
| "The predicted versus observed plasma concentration-time profiles for alfentanil and lidocaine were similar, such that the pharmacokinetic changes associated with Child-Pugh class A, B and C liver cirrhosis were adequately described." | 3.74 | Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. ( Edginton, AN; Willmann, S, 2008) |
| "Impaired renal ability to excrete urine in liver cirrhosis is related to the activation of intrahepatic adenosine receptors, and this is consistent with our previous data showing renal regulation through a hepatorenal neural mechanism activated by intrahepatic adenosine." | 3.73 | Blockade of intrahepatic adenosine receptors improves urine excretion in cirrhotic rats induced by thioacetamide. ( Fan, YJ; Lautt, WW; Ming, Z; Yang, X, 2005) |
| "The study group consisted of 7 patients with compensated liver cirrhosis and 10 healthy volunteers, all individuals were given a single 280 mg dose of caffeine perorally." | 3.71 | [Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ( Perlík, F; Pucelíková, T; Slanar, O, 2001) |
| "In an exploratory study the 24-h urinary excretion pattern of caffeine and 14 of its major metabolites was studied in 32 volunteers (adults, adolescents and children), 14 patients either with end stage renal disease or liver cirrhosis, 7 heavy smokers and 27 patients on therapy with cimetidine, allopurinol, theophylline or phenytoin." | 3.68 | Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. ( Bircher, J; Brandes, A; Compagnone, D; Hille, H; Münch, B; Ullrich, D, 1992) |
| "Pharmacokinetics of theophylline were determined in patients with liver cirrhosis and idiopathic portal hypertension with reference to estimated hepatic blood flow assessed by indocyanine green (ICG)." | 3.68 | [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ( Kanakubo, Y; Nomura, F; Ohnishi, K; Ohto, M; Rikihisa, T; Takeda, Y, 1991) |
| "The effect of cimetidine treatment, 1 g daily over 6 days, on the disposition of theophylline was studied in nine patients with liver cirrhosis and in nine patients without liver disease." | 3.67 | The inhibition of drug metabolism by cimetidine in patients with liver cirrhosis. ( Gugler, R; Hansen, HH; Jensen, JC; Wolf, M, 1984) |
| "Apparent pharmacokinetic parameters of caffeine elimination from the circulation were determined in 27 patients with histologically confirmed liver cirrhosis, 8 patients with miscellaneous liver disease, and 8 patients with other than liver disease." | 3.67 | Correlation of caffeine elimination and Child's classification in liver cirrhosis. ( Gerok, W; Haag, K; Holstege, A; Staiger, M, 1989) |
| "We have studied the pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis, patients with chronic renal failure, and healthy subjects, and have assessed the predictive value of routine tests of liver function and renal function (creatinine clearance) for theophylline and enprofylline total body clearances." | 3.67 | The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ( de Jong, PE; de Zeeuw, RA; Ekman, I; Gips, CH; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1988) |
| "In patients with acute hepatitis, cholestasis, and compensated or decompensated liver cirrhosis the kinetics and urinary excretion of theophylline and metabolites were investigated following intravenous administration (193 mg)." | 3.66 | Pharmacokinetics and metabolism of theophylline in patients with liver diseases. ( Lissner, R; Richter, E; Schuppan, D; Staib, AH; von Bomhard, G; Zilly, W, 1980) |
| "Subjects with liver cirrhosis and chronic hepatitis, as well as healthy volunteers, were given the oral dose of 300 mg caffeine." | 2.71 | Serum metabolite/caffeine ratios as a test for liver function. ( Flieger, J; Jodynis-Liebert, J; Juszczyk, J; Matuszewska, A, 2004) |
| "Adenosine is a potent vasoactive substance that may be responsible for mediating the altered haemodynamics found in patients with cirrhosis." | 2.68 | Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. ( Bouchier, IA; Forrest, EH; Hayes, PC, 1997) |
| " Therefore, the aim of this study was to evaluate the influence of chronic hepatitis (CH), liver cirrhosis (LC), and other covariates on theophylline clearance by population pharmacokinetic (PPK) analysis." | 1.56 | Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. ( Araki, H; Hirota, T; Ieiri, I; Kashihara, Y; Kurata, Y; Muraki, S, 2020) |
| "Theophylline treated rats exhibited a significant decrease in hepatic vacuolation, apoptosis, leucocyte infiltration, and accumulation of collagen fibers in comparison to the Con A group." | 1.42 | Theophylline, an old drug with multi-faceted effects: Its potential benefits in immunological liver injury in rats. ( Elsirafy, OM; Hamam, GG; Hasanin, AH; Hussein, RM; Kawy, HS; Wahba, YS, 2015) |
| " These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis." | 1.28 | A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. ( Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992) |
| " This dosage did not significantly change other hemodynamic values, oxygen (O2) consumption, or sympathoadrenal activity." | 1.28 | Effects of theophylline on hemodynamics and tissue oxygenation in patients with cirrhosis. ( Bacq, Y; Champigneulle, B; Gaudin, C; Kleber, G; Lebrec, D; Moreau, R; Poo, JL, 1992) |
| "001) and no significant differences were observed in the pharmacokinetic data derived from the respective concentration-time curves." | 1.28 | The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ( Chakraborty, J; Marks, V; Morgan, MY; Scott, NR; Stambuk, D, 1989) |
| " In cirrhosis the bioavailability of a flow-dependent drug increases because of both portosystemic shunting and hepatocyte dysfunction." | 1.27 | Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. ( Buccino, G; Cocciolo, M; Colli, A; Parravicini, R; Scaltrini, G, 1988) |
| " The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28." | 1.26 | Pharmacokinetics of theophylline in hepatic disease. ( Imhoff, TE; Jusko, WJ; Lee, RV; Mangione, A; Shum, LY, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (53.85) | 18.7374 |
| 1990's | 10 (25.64) | 18.2507 |
| 2000's | 6 (15.38) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Kurata, Y | 1 |
| Muraki, S | 1 |
| Kashihara, Y | 1 |
| Hirota, T | 1 |
| Araki, H | 1 |
| Ieiri, I | 1 |
| Hussein, RM | 1 |
| Elsirafy, OM | 1 |
| Wahba, YS | 1 |
| Kawy, HS | 1 |
| Hasanin, AH | 1 |
| Hamam, GG | 1 |
| Edginton, AN | 1 |
| Willmann, S | 1 |
| GIRARD, M | 1 |
| FRAISSE, H | 1 |
| DISSARD, P | 1 |
| POTTON, F | 1 |
| ADAMSKA-MARCINKOWSKA, H | 1 |
| SCHENNETTEN, FP | 1 |
| Jodynis-Liebert, J | 1 |
| Flieger, J | 1 |
| Matuszewska, A | 1 |
| Juszczyk, J | 1 |
| Ming, Z | 1 |
| Fan, YJ | 1 |
| Yang, X | 1 |
| Lautt, WW | 1 |
| Orlando, R | 1 |
| Padrini, R | 1 |
| Perazzi, M | 1 |
| De Martin, S | 1 |
| Piccoli, P | 1 |
| Palatini, P | 1 |
| Baer, DM | 1 |
| Wood, DC | 1 |
| Gugler, R | 1 |
| Wolf, M | 1 |
| Hansen, HH | 1 |
| Jensen, JC | 1 |
| Radomski, L | 1 |
| Park, GD | 1 |
| Goldberg, MJ | 1 |
| Spector, R | 1 |
| Johnson, GF | 1 |
| Quee, CK | 1 |
| Iafrate, RP | 1 |
| Gotz, VP | 1 |
| Robinson, JD | 1 |
| Lupkiewicz, SM | 1 |
| Kuntz, HD | 1 |
| May, B | 1 |
| Staib, AH | 1 |
| Schuppan, D | 1 |
| Lissner, R | 1 |
| Zilly, W | 1 |
| von Bomhard, G | 1 |
| Richter, E | 1 |
| Holstege, A | 2 |
| Kurz, M | 1 |
| Weinbeck, M | 1 |
| Gerok, W | 2 |
| Forrest, EH | 2 |
| Bouchier, IA | 1 |
| Hayes, PC | 2 |
| Stanley, AJ | 1 |
| Dabos, KJ | 1 |
| MacGilchrist, AJ | 1 |
| Froomes, PR | 1 |
| Morgan, DJ | 1 |
| Smallwood, RA | 1 |
| Angus, PW | 1 |
| Self, TH | 1 |
| Chafin, CC | 1 |
| Soberman, JE | 1 |
| Perlík, F | 1 |
| Pucelíková, T | 1 |
| Slanar, O | 1 |
| Mangione, A | 1 |
| Imhoff, TE | 1 |
| Lee, RV | 1 |
| Shum, LY | 1 |
| Jusko, WJ | 1 |
| Piafsky, KM | 2 |
| Sitar, DS | 1 |
| Rangno, RE | 2 |
| Ogilvie, RI | 2 |
| Shand, DG | 1 |
| Sitar, D | 1 |
| Ullrich, D | 1 |
| Compagnone, D | 1 |
| Münch, B | 1 |
| Brandes, A | 1 |
| Hille, H | 1 |
| Bircher, J | 1 |
| Tanaka, E | 1 |
| Ishikawa, A | 1 |
| Yamamoto, Y | 1 |
| Osada, A | 1 |
| Tsuji, K | 1 |
| Fukao, K | 1 |
| Misawa, S | 1 |
| Iwasaki, Y | 1 |
| Moreau, R | 1 |
| Champigneulle, B | 1 |
| Gaudin, C | 1 |
| Poo, JL | 1 |
| Kleber, G | 1 |
| Bacq, Y | 1 |
| Lebrec, D | 1 |
| Cukier, A | 1 |
| Strauss, E | 1 |
| Terra Filho, M | 1 |
| Santos, SR | 1 |
| Vargas, FS | 1 |
| Nomura, F | 1 |
| Ohnishi, K | 1 |
| Ohto, M | 1 |
| Takeda, Y | 1 |
| Rikihisa, T | 1 |
| Kanakubo, Y | 1 |
| Amodio, P | 1 |
| Lauro, S | 1 |
| Rondana, M | 1 |
| Crema, G | 1 |
| Merkel, C | 1 |
| Gatta, A | 1 |
| Ruol, A | 1 |
| Scott, NR | 1 |
| Stambuk, D | 1 |
| Chakraborty, J | 1 |
| Marks, V | 1 |
| Morgan, MY | 1 |
| Staiger, M | 1 |
| Haag, K | 1 |
| Colli, A | 1 |
| Buccino, G | 1 |
| Cocciolo, M | 1 |
| Parravicini, R | 1 |
| Scaltrini, G | 1 |
| Kraan, J | 1 |
| Jonkman, JH | 1 |
| Koëter, GH | 1 |
| Gips, CH | 1 |
| de Jong, PE | 1 |
| van der Mark, TW | 1 |
| Ekman, I | 1 |
| de Zeeuw, RA | 1 |
| Schatz, H | 1 |
| Queneau, P | 1 |
| Le Guyader, J | 1 |
| Pont, M | 1 |
| Dohrmann, RE | 1 |
| Konrad, D | 1 |
| Sawade, H | 1 |
| Kühl, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study[NCT02414880] | Phase 4 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis[NCT00244569] | Phase 3 | 120 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for theophylline and Liver Cirrhosis
| Article | Year |
|---|---|
Effect of disease states on theophylline serum concentrations: are we still vigilant?
Topics: Cystic Fibrosis; Fever; Heart Failure; Humans; Liver Cirrhosis; Pulmonary Heart Disease; Theophyllin | 2000 |
6 trials available for theophylline and Liver Cirrhosis
| Article | Year |
|---|---|
Serum metabolite/caffeine ratios as a test for liver function.
Topics: Adult; Caffeine; Female; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis; Liver Function Tests; M | 2004 |
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Topics: Adult; Antidepressive Agents; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inh | 2006 |
Model for theophylline overdose treatment with oral activated charcoal.
Topics: Adult; Aged; Aminophylline; Charcoal; Female; Humans; Infusions, Parenteral; Kinetics; Liver Cirrhos | 1984 |
Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis.
Topics: Adenosine; Administration, Oral; Adult; Aged; Hemodynamics; Humans; Liver Cirrhosis; Middle Aged; Re | 1997 |
Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study.
Topics: Adenosine; Aged; Ascites; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Mineralocorticoid Rece | 1998 |
Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis.
Topics: Acetaminophen; Adult; Female; Humans; Liver Cirrhosis; Male; Metabolic Clearance Rate; Middle Aged; | 1999 |
32 other studies available for theophylline and Liver Cirrhosis
| Article | Year |
|---|---|
Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis.
Topics: Adult; Hepatitis, Chronic; Humans; Kinetics; Liver Cirrhosis; Retrospective Studies; Theophylline | 2020 |
Theophylline, an old drug with multi-faceted effects: Its potential benefits in immunological liver injury in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Caspase 3; Chemical and Drug Induced Liv | 2015 |
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Topics: Alfentanil; Humans; Levetiracetam; Lidocaine; Liver Cirrhosis; Models, Biological; Piracetam; Theoph | 2008 |
[Diuretic action of a mercury theophylline compound in alcoholic cirrhosis].
Topics: Alcoholism; Anti-Infective Agents; Diuretics; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; M | 1954 |
[Comparative studies on the diuretic effect of diurazine and other commonly used diuretics].
Topics: Acetazolamide; Chlorothiazide; Diuretics; Heart Failure; Humans; Liver Cirrhosis; Organomercury Comp | 1963 |
[HOW DOES THE HEPATOCARDIAL SYNDROME AFFECT THE CARDIOVASCULAR SYSTEM?WITH DIRECTIONS FOR DRUG AND DIET THERAPY].
Topics: Cardiovascular Diseases; Cardiovascular System; Diet; Diet Therapy; Diuretics; Heart Failure; Hepati | 1963 |
Blockade of intrahepatic adenosine receptors improves urine excretion in cirrhotic rats induced by thioacetamide.
Topics: Adenosine; Animals; Female; Injections, Intravenous; Kidney; Liver; Liver Circulation; Liver Cirrhos | 2005 |
Artifactual lowering of the total bilirubin value.
Topics: Azo Compounds; Bilirubin; Chemistry, Clinical; Humans; In Vitro Techniques; Indicators and Reagents; | 1967 |
The inhibition of drug metabolism by cimetidine in patients with liver cirrhosis.
Topics: Adult; Aged; Cimetidine; Drug Antagonism; Female; Half-Life; Humans; Liver Cirrhosis; Male; Middle A | 1984 |
Computer-simulated conversion from intravenous to sustained-release oral theophylline.
Topics: Administration, Oral; Adult; Asthma; Computers; Delayed-Action Preparations; Drug Administration Sch | 1982 |
[Theophylline elimination in chronic liver diseases].
Topics: Half-Life; Hepatitis; Humans; Liver Cirrhosis; Metabolic Clearance Rate; Theophylline | 1982 |
Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
Topics: Cholestasis; Hepatitis; Humans; Kinetics; Liver Cirrhosis; Liver Diseases; Theophylline | 1980 |
Excretion of caffeine and its primary degradation products into bile.
Topics: Adult; Aged; Bile; Bilirubin; Caffeine; Chromatography, High Pressure Liquid; Female; Humans; Liver | 1993 |
[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
Topics: Caffeine; Female; Humans; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Saliva; Theophyl | 2001 |
Pharmacokinetics of theophylline in hepatic disease.
Topics: Half-Life; Humans; Liver Cirrhosis; Middle Aged; Saliva; Theophylline | 1978 |
Theophylline disposition in patients with hepatic cirrhosis.
Topics: Adult; Biotransformation; Blood Proteins; Female; Half-Life; Humans; Informed Consent; Kinetics; Liv | 1977 |
Drug disposition in liver disease.
Topics: Blood Proteins; Half-Life; Humans; Inactivation, Metabolic; Liver; Liver Cirrhosis; Liver Diseases; | 1977 |
Theophylline in liver disease.
Topics: Biotransformation; Humans; Kinetics; Liver Cirrhosis; Theophylline | 1977 |
Proceedings: The clinical pharmacology of theophylline and its pharmacokinetics in pulmonary edema and cirrhosis.
Topics: Adult; Child; Humans; Kinetics; Liver Cirrhosis; Pulmonary Edema; Theophylline | 1976 |
Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.
Topics: Adolescent; Adult; Age Factors; Allopurinol; Caffeine; Child; Cimetidine; Drug Interactions; Female; | 1992 |
A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
Topics: Adult; Caffeine; Evaluation Studies as Topic; Female; Humans; Liver; Liver Cirrhosis; Male; Methods; | 1992 |
Effects of theophylline on hemodynamics and tissue oxygenation in patients with cirrhosis.
Topics: Adult; Catecholamines; Dose-Response Relationship, Drug; Female; Heart Rate; Hemodynamics; Humans; I | 1992 |
Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis.
Topics: Adolescent; Adult; Aged; Aminophylline; Animals; Female; Half-Life; Humans; Injections, Intravenous; | 1992 |
[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
Topics: Adult; Aged; Chronic Disease; Female; Humans; Liver; Liver Circulation; Liver Cirrhosis; Liver Disea | 1991 |
Theophylline pharmacokinetics and liver function indexes in chronic liver disease.
Topics: Adult; Aged; Female; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis; Male; Metabolic Clearance R | 1991 |
The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.
Topics: Adult; Aged; Caffeine; Female; Half-Life; Humans; Liver Cirrhosis; Liver Function Tests; Male; Middl | 1989 |
Correlation of caffeine elimination and Child's classification in liver cirrhosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Caffeine; Chromatography, High Pressure Liquid | 1989 |
Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.
Topics: Adult; Aged; Female; Humans; Hypertension, Portal; Lidocaine; Liver Cirrhosis; Male; Metabolic Clear | 1988 |
The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.
Topics: Adult; Aged; Bronchodilator Agents; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; | 1988 |
[The pancreatic beta-cell in the field of current diabetology].
Topics: Blood Glucose; Cyclic AMP; Diabetes Mellitus; Glucagon; Glucose Tolerance Test; Glyburide; Growth Ho | 1974 |
[Clinical study of heptaminol acefyllinate].
Topics: Aged; Amino Alcohols; Dyspnea; Female; Heart Diseases; Humans; Liver Cirrhosis; Male; Middle Aged; N | 1967 |
[Clinical studies on the effectiveness of Xantinol-nicotinate in chronic hepatitis and liver cirrhosis].
Topics: Adult; Chronic Disease; Female; Hepatitis; Humans; Liver Cirrhosis; Liver Function Tests; Male; Midd | 1968 |